<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:arxiv="http://arxiv.org/schemas/atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title>q-bio.OT updates on arXiv.org</title>
    <link>http://rss.arxiv.org/rss/q-bio.OT</link>
    <description>q-bio.OT updates on the arXiv.org e-print archive.</description>
    <atom:link href="http://rss.arxiv.org/rss/q-bio.OT" rel="self" type="application/rss+xml"/>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <language>en-us</language>
    <lastBuildDate>Tue, 06 Jan 2026 03:20:58 +0000</lastBuildDate>
    <managingEditor>rss-help@arxiv.org</managingEditor>
    <pubDate>Mon, 05 Jan 2026 00:00:00 -0500</pubDate>
    <skipDays>
      <day>Sunday</day>
      <day>Saturday</day>
    </skipDays>
    <item>
      <title>Personalized Forecasting of Glycemic Control in Type 1 and 2 Diabetes Using Foundational AI and Machine Learning Models</title>
      <link>https://arxiv.org/abs/2601.00613</link>
      <description>arXiv:2601.00613v1 Announce Type: new 
Abstract: Background: Accurate week-ahead forecasts of continuous glucose monitoring (CGM) derived metrics could enable proactive diabetes management, but relative performance of modern tabular learning approaches is incompletely defined.
  Methods: We trained and internally validated four regression models (CatBoost, XGBoost, AutoGluon, tabPFN) to predict six weekahead CGM metrics (TIR, TITR, TAR, TBR, CV, MAGE, and related quantiles) using 4,622 case-weeks from two cohorts (T1DM n=3,389; T2DM n=1,233). Performance was assessed with mean absolute error (MAE) and mean absolute relative difference (MARD); quantile classification was summarized via confusion-matrix heatmaps.
  Results: Across T1DM and T2DM, all models produced broadly comparable performance for most targets. For T1DM, MARD for TIR, TITR, TAR and MAGE ranged 8.5 to 16.5% while TBR showed large MARD (mean ~48%) despite low MAE. AutoGluon and tabPFN showed lower MAE than XGBoost for several targets (e.g., TITR: p&lt;0.01; TAR/TBR: p&lt;0.05 to 0.01). For T2DM MARD ranged 7.8 to 23.9% and TBR relative error was ~78%; tabPFN outperformed other models for TIR (p&lt;0.01), and AutoGluon/ tabPFN outperformed CatBoost/XGBoost on TAR (p&lt;0.05). Inference time per 1,000 cases varied markedly (PFN 699 s; AG 2.7 s; CatBoost 0.04 s, XGBoost 0.04 s).
  Conclusions: Week-ahead CGM metrics are predictable with reasonable accuracy using modern tabular models, but low-prevalence hypoglycemia remains difficult to predict in relative terms. Advanced AutoML and foundation models yield modest accuracy gains at substantially higher computational cost.</description>
      <guid isPermaLink="false">oai:arXiv.org:2601.00613v1</guid>
      <category>q-bio.OT</category>
      <pubDate>Mon, 05 Jan 2026 00:00:00 -0500</pubDate>
      <arxiv:announce_type>new</arxiv:announce_type>
      <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
      <dc:creator>Simon Lebech Cichosz, Stine Hangaard, Thomas Kronborg, Peter Vestergaard, Morten Hasselstr{\o}m Jensen</dc:creator>
    </item>
  </channel>
</rss>
